92309-29-0

Basic information

• Product Name: Imipenem-Cilastatin sodium hydrate
• Synonyms: Primaxin;Thienam;Tienam 500;IMipeneM and Cilastatin SodiuM with SodiuM Bicarbonate;7-[(2S)-2-amino-2-carboxy-ethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopro panecarbonyl]amino]hept-2-enoic acid: (5R)-3-[2-(aminomethylideneamino )ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene -2-carboxylic acid;Imipenem-Cilastatin sodium hydrate;Sodium (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate;1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-, mixt. with (2Z)-7-(((2R)-2-amino-2-carboxyethyl)thio)-2-((((1S)-2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic acid
• CAS NO: 92309-29-0
• Molecular Formula: C28H43N5O9S2
• Molecular Weight: 697.8
• EINECS: 1592732-453-0
• Mol File: 92309-29-0.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 990.4 °C at 760 mmHg
• Flash Point: 552.8 °C
• Appearance: /
• Vapor Pressure: 7.13E-19mmHg at 25°C
• CAS DataBase Reference: Imipenem-Cilastatin sodium hydrate(CAS DataBase Reference)
• NIST Chemistry Reference: Imipenem-Cilastatin sodium hydrate(92309-29-0)
• EPA Substance Registry System: Imipenem-Cilastatin sodium hydrate(92309-29-0)

Safety Data

• Hazardous Substances Data: 92309-29-0(Hazardous Substances Data)

Usage

Drug interactions

Potentially hazardous interactions with other drugs Antiepileptics: reduced valproate concentration - avoid. Antivirals: convulsions reported with concomitant administration of ganciclovir and valganciclovir. Ciclosporin: variable reports of increase / no change in ciclosporin levels, and of neurotoxicity.

Metabolism

When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I, an enzyme in the brush border of the renal tubules, to inactive, nephrotoxic metabolites, with only about 5 to 40 or 45% of a dose excreted in the urine as unchanged active drug. Cilastin inhibits the metabolism of imipenem. When given with cilastatin about 70% of an intravenous dose of imipenem is recovered unchanged in the urine within 10 hours. Cilastatin is also excreted mainly in the urine, the majority as unchanged drug and about 12% as N-acetyl cilastatin. Less than 1% of imipenem is excreted via the bile in the faeces.

InChI:InChI=1/C16H26N2O5S.C12H17N3O4S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21;1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23);5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/b12-6-;/t10-,11-;6-,7-,9-/m11/s1